This inventor holds 7 USPTO granted patents and 6 published patent applications. Top assignees: Zeneca Limited, Imperial Chemical Company. Active years: 1996-1998.
Company Filing History:
Years Active: 1996-1998
Title: Paul Francis Jackson: Innovator in Neurological Therapeutics
Introduction
Paul Francis Jackson is a notable inventor based in Chadds Ford, Pennsylvania. He has made significant contributions to the field of neurological therapeutics, holding a total of seven patents. His work focuses on developing innovative compounds aimed at treating various neurodegenerative disorders.
Latest Patents
Among his latest patents is a groundbreaking invention titled "Substituted nitrogen heterocycles - Antagonists at the NMDA receptor complex." This patent involves benzodiazepines that have a hydroxy, alkoxy, or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl, or heteroaryl substituent. These compounds are designed for the treatment of stroke and other neurodegenerative disorders. Another significant patent is for "Therapeutic compositions - Benzodiazepine compounds," which includes pharmaceutical compositions containing these compounds and methods for treating neurological disorders.
Career Highlights
Throughout his career, Paul has worked with prominent companies such as Zeneca Limited and Imperial Chemical Company. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.
Collaborations
Paul has collaborated with notable individuals in his field, including Marc Jerome Chapdelaine and Timothy W. Davenport. These partnerships have further enhanced his research and development efforts.
Conclusion
Paul Francis Jackson is a distinguished inventor whose work in neurological therapeutics has the potential to impact the treatment of various disorders significantly. His innovative patents and collaborations reflect his commitment to advancing medical science.